Thank you
This live web event has ended. Thank you for attending.
Description
Measurable residual disease
by multiparametric flow cytometry
in acute lymphoblastic leukemia
Join us for an overview of multiparametric flow
cytometry for MRD testing in B-ALL, including:
- An in-depth review of the methodology and special considerations
- Data analysis, reporting, and clinical decision-making based on MRD results
-
Patient cases that demonstrate the use of multiparametric flow cytometry
for MRD testing in B-ALL
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within.
Sponsored by Amgen
USA-103-80918